Abstract:Abstract BACKGROUND AND AIMS Sarcopenia is common in chronic kidney disease (CKD) and is associated with increased mortality and morbidity. Sarcopenia in CKD can be defined as a decreased muscle mass, mainly due to the catabolic state caused by the uremic environment. Malnutrition and inflammation are also common in sarcopenic patients. In this study, we aimed to investigate the prevalence of sarcopenia defined as low muscle mass determined by Psoas Muscle Index (PMI) in waitlisted end-stage renal disease (ESRD) patients and its association between ‘Prognostic Nutritional Index (PNI)’, ‘C-reactive protein (CRP) to Albumin Ratio (CAR)’ and mortality. METHOD ESRD patients registered to national kidney transplant waiting list and had abdomen CT at admission were included in the study. Kidney donor candidates were constituted as healthy controls. PMI (cm2/m2) were calculated by proportioning the psoas muscle area detected in the abdomen CT with the square of the height. The PMI of the controls at the fifth percentile according to gender was accepted as the limit value for sarcopenia. PNI and CAR were calculated using albumin, CRP and absolute lymphocyte count. The associations between PMI, PNI, CAR and all-cause mortality were investigated. RESULTS A total of 162 ESRD patients and 87 age matched healthy controls were included in the study. The mean age of the patients was 44.7 ± 14.2 years and follow-up time was 3.37 (0.35–9.60) years. The mean PMI were similar between the groups (5.24 ± 1.71 versus 5.48 ± 1.87 cm2/m2 P = 0.302). While prevalence of sarcopenia (16.7% versus 3.4%, P = 0.002) and CAR [1.47 (0.12–37.10) versus 0.74 (0.21–10.20), P < 0.001] was higher; PNI [40 (20.4–52.2) versus 44 (36.1–53.0), P < 0.001] was lower in ESRD patients than controls. When ESRD patients compared according to sarcopenia PMI [3.45 ± 0.9 versus 5.59 ± 1.6, P < 0.001] and PNI [39 (20.4–51) versus 41 (23–52.2), P = 0.005] was significantly lower and CAR [2.03 (0.28–34.65) versus 1.28 (0.12–37.1), P = 0.041] was higher in sarcopenic ESRD group than non-sarcopenic ESRD group (Table 1). In the correlation analysis, PMI was positively correlated with PNI (r = 0.246, P = 0.002), no correlated with CAR (r = −0.061, P = 0.445). In the follow-up, 67 waitlisted patients had been transplanted. In the five-year survival analysis, the non-sarcopenic transplant group [95% CI: 4.612–5.123 versus 95% CI: 2.721–5.413, P = 0.001] had better survival than sarcopenic transplant group (Figure 1). Mortality rates were similar in both sarcopenic transplant group and non-sarcopenic-non-transplant group. Multivariate regression analysis showed that sarcopenia (HR: 10.277, 95% CI: 3.912–27.000, P < 0.001), not having a transplant (HR: 3.949, 95% CI: 1.301–11.993, P = 0.015), low PNI (HR: 3.532, 95% CI: 1.303–9.574, P = 0.013) and duration of renal replacement therapy (HR: 1.009, 95% CI: 1.002–1.015, P = 0.008) were independent risk factors for mortality in all ESRD group. CONCLUSION In this study we observed that sarcopenia, as defined by low muscle mass, is almost seen five times more frequent in ESRD patients than controls and positively correlated with PNI. Sarcopenia is an independent risk factor for mortality in waitlisted patients.

Psoas Muscle Index As An Independent Risk Factor Predictive Of Increased Post Operative Length Of Stay In Orthotopic Heart Transplant Candidates

Psoas Muscle Index Predicts 90 Day Mortality In Patients Undergoing Left Ventricular Assist Device Implantation

Preoperative Computed Tomography-Assessed Skeletal Muscle Index is a Novel Prognostic Factor in Patients with Hepatocellular Carcinoma Following Hepatectomy: a Meta-Analysis.

Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis

Impact of Psoas Muscle Area Index on Short- and Mid-Term Mortality in Patients Undergoing Valve Surgery for Infective Endocarditis: A Retrospective Analysis

The psoas muscle index as a useful predictor of total hip arthroplasty outcomes

Effects of Sarcopenia and Malnutrition on Short-Term Prognosis after Minimally Invasive Pancreaticoduodenectomy

Psoas Muscle Index and Density as Prognostic Predictors in Patients Hospitalized with Acute Pancreatitis

Presence of Sarcopenia before Kidney Transplantation Is Associated with Poor Outcomes

Low muscle mass determined by psoas muscle area does not correlate with dual-energy x-ray absorptiometry or total lumbar muscle mass scores: A prospective cohort study of patients undergoing vascular surgery

MO956: Sarcopenia Predicts Mortality in Renal Transplant Candidates

The Impact of Sarcopenia in the Long-Term Survival of Patients following Complex Endovascular Aortic Surgery for Thoracoabdominal Aortic Aneurysms

Sarcopenia predicts perioperative adverse events following complex revision surgery for the thoracolumbar spine

Is the measurement of sarcopenia associated with oncological disease in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?

Association between psoas major muscle mass and CPET performance and long-term survival following major colorectal surgery: A retrospective cohort study

Impact of Sarcopenia on the Survival of Patients Undergoing Liver Transplantation for Decompensated Liver Cirrhosis

Impact of Sarcopenia on Post-Liver Transplant Hospitalization: Insights From a South Asian Cohort

Impact of sarcopenia on outcomes following intra-arterial therapy of hepatic malignancies

Low Psoas-Muscle index is associated with decreased survival in hepatocellular carcinoma treated with transarterial chemoembolization

Sarcopenia Is Associated With Increased Mortality in Patients With Necrotizing Soft Tissue Infections

Use of Skeletal Muscle Index as a Predictor of Wait‐List Mortality in Patients With End‐Stage Liver Disease